UCB’s phase IIa study results of Bepranemab in early Alzheimer’s Disease selected for late-breaking symposium at 2024 CTAD Meeting
UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild… read more.
